Suppr超能文献

Will an International Qualitative Study of Crohn's Disease Patient Experiences and Preferences Evolve the Future of Disease Monitoring?

作者信息

Castrillon Rocio

机构信息

Crohn's & Colitis Foundation, New York, New York, USA.

出版信息

Crohns Colitis 360. 2023 Feb 25;5(2):otad013. doi: 10.1093/crocol/otad013. eCollection 2023 Apr.

Abstract
摘要

相似文献

9
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With Vedolizumab Professor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota.特别会议回顾版:欧洲克罗恩病和结肠炎组织(ECCO)第14届大会炎症性肠病亮点:对第14届欧洲克罗恩病和结肠炎组织(ECCO)大会部分演讲的回顾 • 2019年3月6 - 9日 • 丹麦哥本哈根• VARSITY:维多珠单抗与阿达木单抗治疗活动性溃疡性结肠炎患者的双盲、双模拟、随机对照试验• 来自VISIBLE 1和2试验的数据分析:维多珠单抗治疗溃疡性结肠炎或克罗恩病患者• 乌帕替尼作为中度至重度活动性溃疡性结肠炎成人诱导治疗的内镜结果改善和黏膜愈合:U - ACHIEVE研究数据• 维多珠单抗治疗溃疡性结肠炎和克罗恩病的长期安全性:GEMINI LTS研究最终结果• 儿童克罗恩病阿达木单抗基于水平的优化治疗(PAILOT)随机对照试验• 抗P19导向的IL - 23抗体mirikizumab维持治疗:中度至重度活动性溃疡性结肠炎患者52周结果• 维多珠单抗和抗TNF治疗在初治溃疡性结肠炎或克罗恩病患者中的真实世界有效性和安全性:EVOLVE研究结果• 靶向释放口服环孢素制剂治疗轻至中度溃疡性结肠炎的随机、多中心、双盲、安慰剂对照研究:疗效结果• 接受维多珠单抗治疗的炎症性肠病患者的真实世界分析 医学教授 胃肠病学和肝病科 梅奥诊所 明尼苏达州罗切斯特
Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 2):1-24.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验